BOSTON, Sept. 20 -- The Dana-Farber Cancer Institute issued the following news release on Sept. 18, 2021: More than half of patients with non-small cell lung cancer (NSCLC) bearing a mutation in the HER2 gene had their tumors stop growing or shrink for an extended time after treatment with a drug that hitches a chemotherapy agent to a highly targeted antibody, an international clinical trial led by investigators at Dana-Farber Cancer Institute has found. The results, to be reported simultaneou  more